From NAFLD to NASH and HCC: Pathogenetic Mechanisms and Therapeutic Insights
The DOI matches its Crossref record.
Abstract
NAFLD is the most common liver disease worldwide but it is the potential evolution to cirrhosis and hepatocellular carcinoma (HCC) that makes NAFLD of such clinical importance. The current work provides an overview of the main mechanims and potential therapeutical insights involved in NAFLD, NASH, fibrosis and HCC progression. Keywords: NAFLD, NASH, fibrosis, microbiota, bacterial translocation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Piscaglia, F., Svegliati‐Baroni, G., Barchetti, A., Pecorelli, A., Marinelli, S., Tiribelli, C., Bellentani, S., & on behalf of the HCC‐NAFLD Italian Study Group (2016) · Hepatology · doi:10.1002/hep.28368 · Cited by 604
“In fact, when confounding factors were eliminated, NAFLDHCC showed a survival fully comparable to that of HCV-HCC.”
BackgroundInfluentialSelf-citationLeoni, S., Tovoli, F., Napoli, L., Serio, I., Ferri, S., & Bolondi, L. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i30.3361 · Cited by 539
AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions
Lonardo, A., Nascimbeni, F., Targher, G., Bernardi, M., Bonino, F., Bugianesi, E., Casini, A., Gastaldelli, A., Marchesini, G., Marra, F., et al. (2017) · Digestive and Liver Disease · doi:10.1016/j.dld.2017.01.147 · Cited by 306
Self-citationPeroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease
Souza-Mello, V. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i8.1012 · Cited by 182
Tosello‐Trampont, A., Krueger, P., Narayanan, S., Landes, S. G., Leitinger, N., & Hahn, Y. S. (2016) · Hepatology · doi:10.1002/hep.28389 · Cited by 142
“NASH is a chronic inflammatory disease leading to the development of fibrosis, cirrhosis, and hepatocellular carcinoma (HCC).((2,3)) Inflammation is a key factor to facilitate the progression of the disease and is initiated by the release of damage-associated molecular patterns (DAMPs) by injured fatty hepatocytes.”
Background
Metadata
- Authors
- De Minicis, S., Day, C., & Svegliati-Baroni, G.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2013-07-01
- Volume
- 19
- Issue
- 29
- Pages
- 5239-5249
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2090674703
- Cited by
- 78
- References
- 0
- FWCI
- 4.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: From NAFLD to NASH and HCC: Pathogenetic Mechanisms and Therapeutic Insights. https://app.cochat.ai/papers/10.2174/1381612811319290006
- The paper
- De Minicis, S., Day, C., & Svegliati-Baroni, G. (2013). From NAFLD to NASH and HCC: Pathogenetic Mechanisms and Therapeutic Insights. Current Pharmaceutical Design. https://doi.org/10.2174/1381612811319290006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.